Tech Company Financing Transactions
RQ Biotechnology Funding Round
RQ Biotechnology, based in London, received $112 million in funding from Frazier Life Sciences, EQT Life Sciences and Forbion Capital Partners.
Transaction Overview
Company Name
Announced On
6/24/2026
Transaction Type
Venture Equity
Amount
$112,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support clinical development of lead programme RQB01 designed to provide seasonal influenza protection with a single administration
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Scale Space, 58 Wood Lane
London, W12 7RZ
UK
London, W12 7RZ
UK
Phone
Undisclosed
Website
Email Address
Overview
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) against seasonal influenza with the goal of providing immediate, powerful and long-lasting protection against the risk of severe viral disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Christian Schade
Chief Executive Officer
Mike Westby
Chief Financial Officer
Alison Seekings
Chief Medical Officer
Gavin Koh
Chief Scientific Officer
Paul Kellam
VP - Bus. Development
Katja Kostelnik
VP - Operations
Hayden Selvadurai
Browse more venture capital transactions:
Prev: 6/24/2026: Moment Energy venture capital transaction
Next: 6/24/2026: Taktile venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs